Latest Conference Articles

March 1st 2021, 7:46pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Immune therapy has evolved rapidly in multiple myeloma, and the field is on the verge of major improvements in outcomes.

March 1st 2021, 3:45pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Although scientific advances in hematology and oncology have been extraordinary, the US health care system faces significant challenges in ensuring that patients receive high-quality, cost-effective care.

February 28th 2021, 11:30am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Several options have emerged for patients with acute myeloid leukemia who are not candidates to receive chemotherapy, with venetoclax-based regimens chief among them.

February 27th 2021, 11:30am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.

February 26th 2021, 10:27pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Peter Martin, MD, discusses potential drug-drug interactions with BTK inhibitors in relapsed/refractory mantle cell lymphoma.

February 26th 2021, 9:06pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Rituximab plus CHOP is not a suitable frontline treatment regimen for all patients with diffuse large B-cell lymphoma, explained Andre H. Goy, MD, who specified that patients with a high-risk International Prognostic Index, elderly patients, and patients with high-risk molecular subtypes require alternative treatment.

February 26th 2021, 12:53am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.

February 26th 2021, 12:01am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Treatment with chimeric antigen receptor T cells has induced unprecedented overall response rates and complete response rates in patients with relapsed/refractory B cell malignancies.

February 25th 2021, 11:30pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.

February 25th 2021, 11:21pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Andrew Ip, MD, MS, discusses the challenges of treating patients with hematologic malignancies and COVID-19.

February 25th 2021, 11:06pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Carlos del Rio, MD, discusses factors to consider when selecting between available vaccines for COVID-19.

February 17th 2021, 3:00pm

Transplantation and Cellular Therapy Meetings

February 17, 2021 — Cord blood–derived natural killer immunotherapy, when paired with high-dose chemotherapy and autologous stem cell transplant, showcased early antitumor activity in patients with B-cell non-Hodgkin lymphoma.

February 14th 2021, 12:14am

Genitourinary Cancers Symposium (ASCO GU)

February 13, 2021 - Cabozantinib resulted in a statistically significant and clinically meaningful prolongation of progression-free survival compared with sunitinib in patients with metastatic papillary renal cell carcinoma.

February 13th 2021, 10:21pm

Genitourinary Cancers Symposium (ASCO GU)

February 13, 2021 - Lenvatinib in combination with pembrolizumab resulted in improved overall survival, progression-free survival, and objective response rate over sunitinib in the frontline treatment of patients with advanced renal cell carcinoma.

February 13th 2021, 9:45pm

Genitourinary Cancers Symposium (ASCO GU)

February 13, 2021 - Belzutifan used in combination with cabozantinib shrank tumors for 88% of patients and the disease control rate was 90% for patients with previously treated advanced clear cell renal cell carcinoma.

February 13th 2021, 9:09pm

Genitourinary Cancers Symposium (ASCO GU)

February 13, 2021 - Certain molecular signatures at baseline were found to be independently linked with long-term response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

February 13th 2021, 8:56pm

Genitourinary Cancers Symposium (ASCO GU)

February 13, 2021 - Bacillus calmette-guérin plus N-803 demonstrated promising responses with a tolerable safety profile when used in patients with BCG-unresponsive, non–muscle-invasive bladder cancer carcinoma in situ

February 13th 2021, 8:05pm

Genitourinary Cancers Symposium (ASCO GU)

February 13, 2021 - Reductions in prostate-specific antigen screening are likely responsible for the recent increase in metastatic prostate cancer cases in the United States.

February 13th 2021, 7:05pm

Genitourinary Cancers Symposium (ASCO GU)

February 13, 2021 - 18F-DCFPyL, an investigational prostate-specific membrane antigen PET imaging agent, was found to detect and localize metastatic lesions with a high correct localization rate and positive predictive value.

February 13th 2021, 6:46pm

Genitourinary Cancers Symposium (ASCO GU)

Patrick Pilie, MD, discusses the impact of adiposity on response to androgen signaling inhibition in patients with metastatic castration-resistant prostate cancer.